CA2368618C - Method of enhancing the efficacy of anti-tumor agents - Google Patents

Method of enhancing the efficacy of anti-tumor agents Download PDF

Info

Publication number
CA2368618C
CA2368618C CA2368618A CA2368618A CA2368618C CA 2368618 C CA2368618 C CA 2368618C CA 2368618 A CA2368618 A CA 2368618A CA 2368618 A CA2368618 A CA 2368618A CA 2368618 C CA2368618 C CA 2368618C
Authority
CA
Canada
Prior art keywords
epo
tumor
cisplatin
group
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2368618A
Other languages
English (en)
French (fr)
Other versions
CA2368618A1 (en
Inventor
M. Steven Piver
David F. Silver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of CA2368618A1 publication Critical patent/CA2368618A1/en
Application granted granted Critical
Publication of CA2368618C publication Critical patent/CA2368618C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
CA2368618A 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents Expired - Fee Related CA2368618C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/300,124 1999-04-27
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
CA2368618A1 CA2368618A1 (en) 2000-11-02
CA2368618C true CA2368618C (en) 2011-03-01

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2368618A Expired - Fee Related CA2368618C (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Country Status (18)

Country Link
US (3) US6171620B1 (enExample)
EP (1) EP1212068A4 (enExample)
JP (1) JP2002542296A (enExample)
KR (1) KR100693796B1 (enExample)
CN (1) CN1188137C (enExample)
AU (1) AU781301B2 (enExample)
BG (1) BG64940B1 (enExample)
BR (1) BR0010082A (enExample)
CA (1) CA2368618C (enExample)
HU (1) HUP0200840A3 (enExample)
IL (1) IL146012A0 (enExample)
MX (1) MXPA01010899A (enExample)
NO (1) NO20015227L (enExample)
NZ (1) NZ514521A (enExample)
PL (1) PL350918A1 (enExample)
RU (1) RU2271829C2 (enExample)
WO (1) WO2000064455A1 (enExample)
ZA (1) ZA200108012B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
IL152428A0 (en) 2000-04-26 2003-05-29 Univ Kingston Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
JP5461386B2 (ja) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
JPWO2019083023A1 (ja) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 癌の治療に使用するための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
CA2368618A1 (en) 2000-11-02
US6171620B1 (en) 2001-01-09
HUP0200840A3 (en) 2003-04-28
US6620779B2 (en) 2003-09-16
US20010000730A1 (en) 2001-05-03
CN1352561A (zh) 2002-06-05
CN1188137C (zh) 2005-02-09
PL350918A1 (en) 2003-02-10
RU2271829C2 (ru) 2006-03-20
KR100693796B1 (ko) 2007-03-12
MXPA01010899A (es) 2003-06-24
AU4486300A (en) 2000-11-10
AU781301B2 (en) 2005-05-12
NO20015227L (no) 2001-12-27
BR0010082A (pt) 2002-01-15
KR20020000557A (ko) 2002-01-05
HUP0200840A2 (hu) 2002-07-29
NZ514521A (en) 2003-07-25
BG106057A (en) 2002-04-30
BG64940B1 (bg) 2006-10-31
NO20015227D0 (no) 2001-10-25
EP1212068A4 (en) 2007-03-14
US6426094B2 (en) 2002-07-30
JP2002542296A (ja) 2002-12-10
ZA200108012B (en) 2003-03-26
IL146012A0 (en) 2002-07-25
US20020198153A1 (en) 2002-12-26
EP1212068A1 (en) 2002-06-12
WO2000064455A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
CA2368618C (en) Method of enhancing the efficacy of anti-tumor agents
Abdel-Razeq et al. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia
Kim et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
EP0224885B1 (en) Antitumor composition.
HU230273B1 (hu) Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
Batist et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.
JPH0296523A (ja) 白金化学療法生成物
Vadhan-Raj PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development
Valley Overview of cancer‐related anemia: focus on the potential role of darbepoetin alfa
Ford et al. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
Kolesar Novel approaches to anemia associated with cancer and chemotherapy
Gonzalez et al. Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma
EP3965734A1 (en) Method for increasing cancer patient's haemoglobin level
CN112168971B (zh) 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用
CN113679720B (zh) 一种取代丁烯酰胺联合铂类化合物的药物组合物及其用途
Inoue et al. Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice
Bellamy Fundamental concepts associated with combining cytotoxic drugs and x-irradiation
Ellerby et al. Preliminary Report on Phase 1 Clinical Experience with Combined cis-diamminedichloride Platinum (II)(PDD) and 5-FU
Dempke Preclinical and clinical effects of erythropoietin in the management of anaemia in patients with non-small cell lung cancer
WO2024216238A2 (en) Use of beta-catenin antagonist and immunomodulator
CN117398467A (zh) 一种预防或治疗滤泡淋巴瘤的联合用药物组合物及其应用
Glaspy Erythropoietins and Erythropoiesis 163 ed, by G. Molineux, MA Foote, and S G. Elliott© 2003 Birkhäuser Verlag/Switzerland
Hopkins et al. Systemic mitomycin C versus cisplatin: comparison of antitumor activity in primary murine bladder cancer
Benasso et al. Analysis of 16 Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck: Implications for Treatment
Lévi et al. and Folinic Acid (Leucovorin) in Patients With Colorectal

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed